Related Experiment Videos
Preclamol and parkinsonian fluctuations
Z Pirtosek1, M Merello, A Carlsson
1Institute for Clinical Neurophysiology, Medical Centre, Ljubljana, Slovenia.
Clinical Neuropharmacology
|December 1, 1993
Summary
Preclamol, a dopamine agonist, showed mild anti-parkinsonian effects with fewer dyskinesias compared to apomorphine. Further research into its therapeutic potential for Parkinson's disease is warranted.
Area of Science:
- Neuroscience
- Pharmacology
- Movement Disorders
Background:
- Parkinson's disease is characterized by motor fluctuations, often managed with dopaminergic agents.
- Preclamol, the (-)enantiomer of 3-PPP (3(3-hydroxyphenyl)-N-n-propyl piperidine), exhibits a mixed dopamine autoreceptor and postsynaptic agonist-antagonist profile.
- Understanding novel therapeutic agents for Parkinsonian fluctuations is crucial.
Purpose of the Study:
- To evaluate the efficacy and tolerability of Preclamol in patients experiencing disabling on-off fluctuations in Parkinson's disease.
- To compare the effects of Preclamol with placebo and subcutaneous apomorphine.
Main Methods:
- A study involving patients with Parkinson's disease and on-off fluctuations.
- Administration of Preclamol, placebo, and subcutaneous apomorphine.
- Assessment of antiakinetic effects and dyskinesia.
Main Results:
- Preclamol demonstrated a mild but clear antiakinetic effect.
- The antiakinetic effect of Preclamol was less potent than that of subcutaneous apomorphine.
- Preclamol induced significantly less dyskinesia compared to subcutaneous apomorphine.
Conclusions:
- Preclamol offers a potential therapeutic option for Parkinson's disease patients with on-off fluctuations.
- Its favorable side effect profile, particularly reduced dyskinesia, warrants further investigation.
- Additional studies are justified to fully explore the therapeutic potential of Preclamol.